LB Pharmaceuticals financials
$37.28−1.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$53.9M | -$22.1M | -$13.9M | -$5.2M |
| Net income | -$51.6M | -$19.1M | -$11.5M | -$3.6M |
| Net margin | — | — | — | — |
| Diluted EPS | $-1.71 | $-0.67 | $-0.45 | $-0.61 |
| EBITDA | -$53.8M | -$22.0M | -$13.8M | -$5.2M |
| Operating cash flow | -$37.6M | -$23.3M | -$18.1M | — |
| Free cash flow | -$38.0M | -$23.3M | -$18.1M | — |
| Diluted shares | 30.1M | 28.2M | 25.7M | 5.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $283.1M | $320.7M | $250.2M | $269.7M |
| Short-term investments | $44.7M | $45.0M | $45.0M | $44.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $361.7M | $393.5M | $312.9M | $320.7M |
| Total liabilities | $29.3M | $14.8M | $11.6M | $10.5M |
| Shareholders' equity | $332.3M | $378.7M | $301.3M | $310.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology